BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sumitomo Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sumitomo Pharma's drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04988555-3087@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Enzomenib: Phase 1/2 readout est. (NCT04988555)
DESCRIPTION:Enzomenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Phase
  1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horize
 n-1)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/enzomenib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04988555
URL:https://assetmemo.bio/drug/enzomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526819-2733@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SMP3124LP: Phase 1/2 readout est. (NCT06526819)
DESCRIPTION:SMP3124LP\, phase 1/2.\nStudy: SMP-3124LP in Adults With Advanc
 ed Solid Tumors\nEstimated primary completion: December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/smp3124lp#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06526819
URL:https://assetmemo.bio/drug/smp3124lp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06753331-8718@assetmemo.bio
DTSTAMP:20261121T005819Z
DTSTART;VALUE=DATE:20301215
DTEND;VALUE=DATE:20301216
SUMMARY:Raguneprocel (Amchepry): Phase 1/2 readout est. (NCT06753331)
DESCRIPTION:Raguneprocel (Amchepry)\, phase 1/2\, Parkinson's Disease.\nStu
 dy: A Multicenter Study to Evaluate Safety\, Tolerability\, and Clinical R
 esponses of DSP-1083 Into Subjects With Parkinson's Disease\nEstimated pri
 mary completion: 15 December 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/raguneprocel-amchepry#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06753331
URL:https://assetmemo.bio/drug/raguneprocel-amchepry#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
